Sugi Predict

Sugi Predict / Compounds / SCHEMBL1334768

SCHEMBL1334768

SCHEMBL1334768

Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(F)cc3)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 13/20 1.00
▸ FGFR1 P11362 12/20 1.00
▸ PDGFRB P09619 10/20 1.00
▸ PDGFRA P16234 10/20 1.00
▸ EGFR P00533 9/20 1.00
▸ ABL1 P00519 8/20 1.00
▸ MAPK14 Q16539 8/20 1.00
▸ KIT P10721 3/20 1.00
▸ WEE1 P30291 2/20 0.82
▸ FGFR2 P21802 1/20 0.82
▸ FGFR4 P22455 1/20 0.82
▸ FGFR3 P22607 1/20 0.82
▸ ACVR1 Q04771 2/20 0.79
▸ STAT5A P42229 1/20 0.79
▸ PKMYT1 Q99640 1/20 0.79
▸ PSEN1 P49768 1/20 0.78
▸ PSEN2 P49810 1/20 0.78
▸ APH1B Q8WW43 1/20 0.78
▸ NCSTN Q92542 1/20 0.78
▸ APH1A Q96BI3 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5764062 0.92 FGFR1 (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL5762046 0.91 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL1249524 0.90 FGFR1 (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL11939526 0.90 FGFR1 (0.84) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL2083696 0.90 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL2081574 0.90 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL868353 0.88 FGFR1 (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL29378902 0.88 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL256711 0.88 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR
SCHEMBL30257377 0.88 SRC (1.00) SRCFGFR1PDGFRBPDGFRAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2233174-B1 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection UNIV EMORY (US) 2016-07-20 — — EP claimed
EP-2233174-A1 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection Emory University (US) 2010-09-29 — — EP claimed
US-20080220497-A1 Modulation of protein functionalities DECIPHERA PHARMACEUTICALS LLC 2008-09-11 — — US claimed
EP-1835934-A2 ENZYME MODULATORS AND TREATMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 — — EP claimed
US-20070078121-A1 Enzyme modulators and treatments DECIPHERA PHARMACEUTICALS, LLC 2007-04-05 — — US claimed
WO-2006071940-A2 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-07-06 — — WO claimed
EP-3434788-B1 CLASSIFICATION AND ACTIONABILITY INDICES FOR LUNG CANCER LIFE TECHNOLOGIES CORP (US) 2023-08-23 — — EP disclosed
EP-2233174-B1 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection UNIV EMORY (US) 2016-07-20 — — EP disclosed
EP-2942349-A1 ENZYME MODULATORS AND TREATMENTS Deciphera Pharmaceuticals, LLC (US) 2015-11-11 — — EP disclosed
US-8765777-B2 Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection EMORY UNIVERSITY (US) 2014-07-01 — — US disclosed
US-8163756-B2 For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, LLC (US) 2012-04-24 — — US disclosed
US-20110281867-A1 COMPOSITIONS AND METHODS OF USE FOR TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-11-17 — — US disclosed
EP-2260849-A1 Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection Emory University (US) 2010-12-15 — — EP disclosed
EP-2233174-A1 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection Emory University (US) 2010-09-29 — — EP disclosed
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
EP-1835934-A2 ENZYME MODULATORS AND TREATMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 — — EP disclosed
US-20070078121-A1 Enzyme modulators and treatments DECIPHERA PHARMACEUTICALS, LLC 2007-04-05 — — US disclosed
WO-2006071940-A2 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281867-A1 COMPOSITIONS AND METHODS OF USE FOR TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION ABL2, ABL1, LCK SRC 7/4885FGFR1 417/4885PDGFRB 199/4885
US-20080220497-A1 Modulation of protein functionalities C1QBP, SERPINA6, CD2BP2 SRC 2604/4885FGFR1 4698/4885PDGFRB 3462/4885
US-20070078121-A1 Enzyme modulators and treatments ABL1, ABL2, LCK SRC 9/4885FGFR1 118/4885PDGFRB 16/4885
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 SRC 69/4885FGFR1 184/4885PDGFRB 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.